Northwest Biotherapeutics Closes $13.8M Offering
Northwest Biotherapeutics, Inc. (Nasdaq: NWBO; NWBOW), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 450,000 shares of common stock and warrants to purchase 225,000 shares, at a public offering price of $4.00 per share and $0.01 per warrant in connection with its previously announced underwritten public offering of 3,000,000 shares of common stock and warrants to purchase 1,500,000 shares of common stock, bringing total gross proceeds from the offering to $13.8 million.
The Warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance.
Aegis Capital Corp. is acting as the sole book-running manager for this offering.
Citybizlist Partner News
- Adelberg, Rudow, Dorf & Hendler, LLC - A Conversation with Paul Meecham, President & CEO of the Baltimore Symphony Orchestra
- Rosenberg Martin Greenberg, LLP - Should Technology Reinvent the Classroom?
- Merritt Properties - Greater Baltimore Board of Realtors Signs Lease for Office Space at Merritt’s Timonium Center
- St. John Properties - Bill Holzman Promoted to VP, Retail Leasing for St. John Properties